Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Recommendation of “Hold” from Analysts

Microbot Medical Inc. (NASDAQ:MBOT) has earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $6.3750.

Several research analysts recently commented on MBOT shares. B. Riley Financial restated a “buy” rating and set a $4.00 target price (down from $5.00) on shares of Microbot Medical in a report on Friday, August 14th. Wall Street Zen raised Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Loop Capital set a $4.00 target price on Microbot Medical in a research note on Wednesday, June 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. Finally, HC Wainwright reiterated a “buy” rating on shares of Microbot Medical in a research report on Wednesday, August 19th.

Institutional Investors Weigh In On Microbot Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. CTC Alternative Strategies Ltd. acquired a new position in Microbot Medical in the 1st quarter worth about $28,000. American Century Companies Inc. bought a new position in Microbot Medical in the 2nd quarter valued at approximately $32,000. Zacks Investment Management bought a new position in Microbot Medical in the 3rd quarter valued at approximately $33,000. Man Group plc acquired a new stake in Microbot Medical during the 4th quarter worth approximately $35,000. Finally, Squarepoint Ops LLC acquired a new stake in Microbot Medical during the 3rd quarter worth approximately $37,000. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Stock Down 0.7%

Microbot Medical stock opened at $1.46 on Friday. The stock has a market capitalization of $98.06 million, a PE ratio of -6.08 and a beta of 1.03. Microbot Medical has a twelve month low of $1.44 and a twelve month high of $4.67. The company has a 50 day moving average of $1.72 and a 200-day moving average of $2.03.

Microbot Medical (NASDAQ:MBOT) last released its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.13 million. Equities analysts anticipate that Microbot Medical will post -0.31 EPS for the current fiscal year.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.